SCHEMBL3359174

SCHEMBL3359174

O=C(O)[C@@H](O)Cc1ccc2c(c1)OCCO2

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM6B O15054 1/20 0.54
CYP3A4 P08684 3/20 0.50
RAB9A P51151 2/20 0.50
PTGS1 P23219 1/20 0.50
PTGS2 P35354 1/20 0.50
KDM4E B2RXH2 1/20 0.50
NPC1 O15118 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
ALDH1A1 P00352 3/20 0.48
USP2 O75604 1/20 0.48
LMNA P02545 1/20 0.48
GAA P10253 1/20 0.48
HPGD P15428 1/20 0.48
ALOX15 P16050 1/20 0.48
HTT P42858 1/20 0.48
HSD17B10 Q99714 1/20 0.48
CYP2D6 P10635 2/20 0.47
CYP1A2 P05177 1/20 0.46
CYP2C19 P33261 1/20 0.46
SLC6A4 P31645 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3350932 1.00 KDM6B (0.54) KDM6BCYP3A4RAB9APTGS1PTGS2
SCHEMBL3350938 1.00 KDM6B (0.54) KDM6BCYP3A4RAB9APTGS1PTGS2
SCHEMBL30052034 0.90 CYP3A4 (0.62) KDM6BCYP3A4RAB9ANPC1ALDH1A1
SCHEMBL2457093 0.90 CYP3A4 (0.62) KDM6BCYP3A4RAB9ANPC1ALDH1A1
SCHEMBL8953616 0.90 CYP3A4 (0.62) KDM6BCYP3A4RAB9ANPC1ALDH1A1
SCHEMBL7516082 0.90 CYP3A4 (0.62) KDM6BCYP3A4RAB9ANPC1ALDH1A1
SCHEMBL3788967 0.83 SLC7A5 (0.55) CYP3A4RAB9APTGS1PTGS2KDM4E
SCHEMBL9514872 0.83 KDM4E (0.50) CYP3A4RAB9APTGS1PTGS2KDM4E
SCHEMBL1744966 0.83 SLC7A5 (0.55) CYP3A4RAB9APTGS1PTGS2KDM4E
SCHEMBL5573727 0.82 SMN1; SMN2 (0.48) CYP3A4RAB9ANPC1SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7696195-B2 Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-04-13 US disclosed
US-20050256099-A1 Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-11-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050256099-A1 Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions CALCRL, CALCR, CALCA KDM6B 4699/4885CYP3A4 1001/4885RAB9A 1600/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.